Cardinal health reports fourth quarter and full year results for fiscal year 2023 at high end of investor day guidance

Fourth quarter revenue increased 13% to $53.5 billion fourth quarter gaap 1 operating earnings were $137 million and gaap diluted loss per share was $0.25 fourth quarter non-gaap operating earnings increased 24% to $560 million and non-gaap diluted eps increased 48% to $1.55 fourth quarter pharmaceutical segment profit increased 12% to $504 million and medical segment profit increased to $82 million generated both operating cash flow and non-gaap adjusted free cash flow of $2.8 billion and returned over $2.5 billion to shareholders in fiscal year 2023 2 fiscal year 2024 non-gaap eps guidance raised to $6.50 to $6.75, from $6.45 to $6.70 dublin, ohio , aug. 15, 2023 /prnewswire/ -- cardinal health (nyse: cah) today reported fourth quarter fiscal year 2023 revenues of $53.5 billion, an increase of 13% from the fourth quarter of last year. gaap operating earnings were $137 million, primarily due to a non-cash, pre-tax goodwill impairment charge of $368 million in the medical segment, which reflects the financial update provided at investor day.
CAH Ratings Summary
CAH Quant Ranking